Watchdog Urges HHS to Investigate Conflicts Among FDA's Peptide Panelists
(MedPage Today) -- A consumer watchdog group is demanding that the HHS Office of Inspector General (OIG) look into potential conflicts of interest among members of an FDA advisory committee that recommended that six peptides be added to the list...
A watchdog group is urging the HHS Office of Inspector General (OIG) to investigate potential conflicts of interest among members of the FDA's 2026 Pharmacy Compounding Advisory Committee (PCAC). The Campaign Legal Center and Margaret Dylus-Yukins, senior legal counsel for ethics, claim several PCAC members had financial ties to the pharmaceutical and peptide industries at the time of their July 2026 meeting.
Despite this, the FDA's Office of Ethics and Integrity (OEI) allowed the members to participate without ethics waivers. The Campaign Legal Center requests the OIG investigate the FDA's ethics decisions to determine if any committee members violated criminal ethics laws by participating without proper waivers.
Written by urgent.news from MedPage Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
